Younger survivors of breast cancer appear to be at higher risk for osteopenia and osteoporosis compared with cancer-free women
If doctors knew a woman’s risk of late distant recurrence, they could recommend extended hormonal therapy only for women who would benefit from it. CTS5 was able to accurately separate the women into groups of low, intermediate, or high risk of late distant recurrence after 5 years of hormonal therapy. The tool found 42% of the women had low late distant recurrence risk, so the risks of extended hormonal therapy outweighed the benefits for these women.
Most of our food containers — from bottles to the linings in aluminum cans to plastic wraps and salad bins — are made using polycarbonate plastics, some of which have bioactive chemicals, like bisphenol A (BPA) and phthalates. These man-made chemicals can leach from the containers or wrappings into the food and drinks they’re holding — especially when they’re heated. Research released earlier this year found that more than 90 percent of bottled water from the world’s leading brands was contaminated with microplastics, sparking a review of plastics in drinking water by the World Health Organization.
Zoledronic acid directly inhibits UGT8 and is already in widespread use. In fact, this medication is on the World Health Organization’s (WHO) list of safe and effective medicines that are deemed “essential for global health.
In one of the largest investigations of its kind conducted to date, researchers found that one-third of the women included in the study had low levels of skeletal muscle mass—a condition known as sarcopenia—at the time of their diagnosis. And having low levels of muscle mass was associated with a higher risk of dying compared with women who had adequate muscle mass, the researchers reported April 5 in JAMA Oncology.
Women with breast cancer who are prescribed aromatase inhibitors (AI) such as Arimidex (anastrozole) and Femara (letrozole) don’t need to take the medication for more than two additional years following the standard five-year treatment period, according to research presented at the 2017 San Antonio Breast Cancer Symposium in December.